Quince Therapeutics, Inc. (NASDAQ:QNCX) CEO Acquires $53,475.00 in Stock

Quince Therapeutics, Inc. (NASDAQ:QNCX) CEO Dirk Thye acquired 77,500 shares of the business’s stock in a transaction on Thursday, August 29th. The shares were purchased at an average cost of $0.69 per share, for a total transaction of $53,475.00. Following the completion of the acquisition, the chief executive officer now directly owns 766,941 shares in the company, valued at $529,189.29. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Quince Therapeutics Stock Performance

NASDAQ QNCX opened at $0.70 on Friday. The stock has a market capitalization of $30.09 million, a price-to-earnings ratio of -0.92 and a beta of 0.94. Quince Therapeutics, Inc. has a one year low of $0.51 and a one year high of $1.43. The company has a debt-to-equity ratio of 0.29, a current ratio of 6.15 and a quick ratio of 6.15. The business’s fifty day moving average is $0.70 and its 200-day moving average is $0.90.

Quince Therapeutics (NASDAQ:QNCX) last released its earnings results on Tuesday, August 13th. The company reported ($0.18) EPS for the quarter.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.